GlaxoSmithKline PLC
14 March 2006
Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons
I give below details of changes in the interests of Directors, Persons
Discharging Managerial Responsibility or Connected Persons in the Ordinary
Shares of GlaxoSmithKline plc.
10 March 2006 Abacus (GSK) Trustees Limited, as trustee of the
GlaxoSmithKline Employee Trust, ("the GSK Trust"), transferred
594,566 Ordinary Shares in the Company to participants in the
SmithKline Beecham Employee Share Option Plan 1991.
The Company was advised of these transactions on 14 March 2006.
The GSK Trust is a discretionary trust of which all employees or former
employees of GlaxoSmithKline plc and its subsidiaries are potential
beneficiaries. Three of the Company's directors, Dr J-P Garnier, Dr T Yamada and
Mr J S Heslop are therefore interested in the shares held in the GSK Trust from
time to time in the same way as other employees or former employees of
GlaxoSmithKline plc and its subsidiaries.
This notification relates to a transaction notified in accordance with
Disclosure Rule 3.1.4R(1)(b).
S M Bicknell
Company Secretary
14 March 2006
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.